Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Melanoma 14Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 7Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Hepatocellular 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Skin Neoplasms 1Seminoma 1Sarcoma 1

Interventions

Nivolumab 1Ipilimumab 1Clinical Laboratory Techniques 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Ipilimumab × 30 days × Clear all
NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡